Glenmark Pharmaceuticals Limited announced the launch of the biosimilar of Adalimumab under a licensing agreement with Cadila Healthcare Ltd. The biosimilar will be marketed by Glenmark under the brand name ADALY. ADALY (Adalimumab) is a TNF inhibiting, anti-inflammatory biologic that binds to tumor necrosis factor (TNFalpha) and reduces inflammatory response.